Catherine Baker, MD
Internal Medicine · Lemont, ILNPI 1871609354
Payments from drug & device makers
Across 155 payments — averaging $19.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$335
- Boehringer Ingelheim$300
- Amgen$268
- E.r. Squibb & Sons, L.L.C.$209
- GSK$190
- Cranial Technologies, Inc$176
- plus $2K from 28 others
What the payments were for
- Food & beverage$3,011100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 20 | $335 |
| Boehringer Ingelheim | 14 | $300 |
| Amgen | 13 | $268 |
| E.r. Squibb & Sons, L.L.C. | 14 | $209 |
| GSK | 10 | $190 |
| Cranial Technologies, Inc | 12 | $176 |
| AbbVie | 8 | $155 |
| Sunovion Pharmaceuticals Inc. | 4 | $150 |
| Otsuka America Pharmaceutical, Inc. | 6 | $143 |
| Pfizer | 5 | $104 |
| Watermark Medical, Inc. | 2 | $98 |
| AstraZeneca | 5 | $96 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $89 |
| Exact Sciences | 4 | $71 |
| Xeris Pharmaceuticals, Inc. | 3 | $60 |
| Novo Nordisk | 4 | $57 |
| Phathom Pharmaceuticals, Inc. | 1 | $56 |
| Phadia US Inc. | 3 | $48 |
| Esperion Therapeutics, Inc. | 2 | $46 |
| Novartis | 2 | $42 |
| Johnson & Johnson | 2 | $39 |
| Sanofi Pasteur Inc. | 2 | $30 |
| Dexcom, Inc. | 1 | $29 |
| Astellas Pharma US Inc | 1 | $25 |
| Genentech USA, Inc. | 2 | $25 |
| Corium, LLC | 1 | $24 |
| Acadia Pharmaceuticals Inc | 1 | $23 |
| Ironshore Pharmaceuticals Inc. | 1 | $22 |
| Teva Pharmaceuticals USA, Inc. | 1 | $20 |
| Inspire Medical Systems, Inc. | 1 | $19 |
| Kowa Pharmaceuticals America, Inc. | 1 | $18 |
| Neurocrine Biosciences, Inc. | 1 | $16 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $15 |
| Merck | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LONHALA MAGNAIR$115
How this compares
$3,011 in reported general payments places this provider in the 85th percentile of 5,182 internal medicine providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 31 | $48,684 |
| EliquisApixaban | 52 | $39,670 |
| TrulicityDulaglutide | 26 | $30,566 |
| JardianceEmpagliflozin | 16 | $22,007 |
| XareltoRivaroxaban | 18 | $19,344 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 15 | $13,091 |
| MounjaroTirzepatide | 11 | $11,731 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 61 | $10,933 |
| LinzessLinaclotide | 12 | $6,763 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 12 | $5,482 |
| Humalog Kwikpen U-100Insulin Lispro | 24 | $4,721 |
| Advair HfaFluticasone Propion/Salmeterol | 13 | $3,922 |
| Atorvastatin Calcium | 261 | $2,990 |
| Potassium Chloride | 71 | $2,844 |
| Levothyroxine Sodium | 178 | $2,713 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $57 | $48,68431 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $335 | $42,29737 claims |
| PfizerEliquis, Paxlovid | $104 | $41,12463 claims |
| Boehringer IngelheimJardiance | $300 | $22,00716 claims |
| Johnson & JohnsonXarelto | $39 | $19,34418 claims |
| GSKTrelegy Ellipta | $190 | $13,09115 claims |
| AbbVieLinzess | $155 | $6,76312 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 5,182 internal medicine providers in Illinois.
Other internal medicine in Lemont
- Dennis LevinsonChicago$25.3M
- Mary BrownRockford$16M
- Andrew BartlettChampaign$4.1M
- Danny SugimotoChicago$4M
- Peter O DonnellChicago$3.9M
- Daniel CatenacciChicago$3.5M
- Jeffrey GeohasEvanston$2.3M
- Patricia WalshChicago$2.1M
- Merle DiamondChicago$1.7M
- Yoko MomoyamaLombard$1.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.